The Global Health Body Sounds Warning Over Acute Lack of Weight-Loss Medications
Fewer than one in 10 patients eligible to benefit from GLP-1 drugs such as Wegovy are able to get them, states the WHO as it releases its first guidance on the therapies.
Considering more than one billion individuals worldwide currently obese, it is urging more widespread and fairer availability to this class of drugs.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"The new guidelines acknowledges that obesity is a chronic disease that can be managed with thorough and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and logistical bottlenecks are key barriers to universal availability to the jabs that can help people shift significant body mass, says the organization.
Skinny Jab Shortage
Even in the present most optimistic outlook, the supply of such drugs could only cover approximately 100 million people – less than 10% of eligible patients, according to the health organization.
The advice encourages countries and companies to widen availability, through strategies including licensing agreements.
A patent on semaglutide – the core component of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Operate
GLP-1 drugs imitate a natural hormone to delay gastric emptying, reduce hunger and increase the sense of being full so people consume fewer calories.
Patients typically start to lose weight after several weeks of commencing the once-weekly jabs.
Studies points to users may regain a significant portion a year later of discontinuing the drug, when their usual food cravings come back.
Being overweight or obese increases your risk for developing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity concerns individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, per the health agency.
